A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer

References

• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, et al. Modified ther-apy with 5-fluorouracil, doxorubicin, and methotrexate in ad-vanced gastric cancer. Cancer 1993; 72 (1): 37–41.
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in pa-tients with non-resectable gastric cancer. Br J Cancer 1995; 71 (3): 587–591.
   PubMed Web of Science ®Google Scholar
• Louvet C, Andre T, Tigaud JM, et al. Phase II study of ox-aliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20 (23): 4543–4548.
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advanced gastric cancer pa-tients. Br J Cancer 2005; 92 (9): 1644–1649.
   PubMed Web of Science ®Google Scholar
• Mauer AM, Kraut EH, Krauss SA, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005; 16 (8): 1320–1325.
   PubMed Web of Science ®Google Scholar
• Garcia AA, Leichman CG, Lenz HJ, et al. Phase II trial of outpatient schedule of paclitaxel in patients with previously un-treated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001; 31 (6): 275-278. Yamaguchi K, Tada M, Horikoshi N, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 5 (2): 90-95.
   Google Scholar
• Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of pacli-taxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12 (8): 1133–1137.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24 (31): 4991–4997.
   PubMed Web of Science ®Google Scholar
• Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10 Suppl 3: 49–58.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Yoshida S,Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006; 24 (14): 2188–2196.
   PubMed Web of Science ®Google Scholar
• Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?. J Clin Oncol 2007; 25 (22): 3188–3190.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Rao S, Starling N, et al. Randomised mul-ticentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesoph-agogastric (OG) cancer: The REAL 2 trial. Proc Am Soc Clin Oncol 2006; 24: abstr LBA4017.
   Google Scholar
• Sumpter K, Harper-Wynne C, Cunningham D, et al. Re-port of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluo-rouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92 (11): 1976–1983.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Ar-beitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26 (9): 1435–1442.
   PubMed Web of Science ®Google Scholar
• Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophos-phamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003; 21 (13): 2466–2473.
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequen-tial versus concurrent combination chemotherapy as postopera-tive adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21 (8): 1431–1439.
   PubMed Web of Science ®Google Scholar
• Gu J, Yamamoto H, Lu X, et al. Low-dose oxaliplatin en-hances the antitumor efficacy of paclitaxel in human gastric can-cer cell lines. Digestion 2006; 74 (1): 19–27.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39 (3): 368–373.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon can-cer. N Engl J Med 2004; 350 (23): 2343–2351.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22 (11): 2084–2091.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GER-COR study. J Clin Oncol 2006; 24 (3): 394–400.
   PubMed Web of Science ®Google Scholar
• van Gerven JM, Moll JW, van den Bent MJ, et al. Pacli-taxel (Taxol) induces cumulative mild neurotoxicity. Eur J Can-cer 1994;30A(8):1074–1077.
   PubMed Web of Science ®Google Scholar